E1.Zhu X, Chen O, Zhang D, Et Al. a Prospective Study on the Treatment of Infantile Spasms

E-References

e1.Zhu X, Chen O, Zhang D, et al. A prospective study on the treatment of infantile spasms with first-line topiramate followed by low-dose ACTH. Epilepsy Research 2011;93:149–154.

e2.Gumus H, Kumandas S, Per H. Levetiracetam monotherapy in newly diagnosed cryptogenic West syndrome. Pediatr Neurol 2007;37:350–353.

e3.Kossoff EH, Pyzik PL, McGrogan JR, Vining EPG, Freeman JM. Efficacy of the ketogenic diet for infantile spasms. Pediatrics 2002;109:780–783.

e4.Hong AM, Turner Z, Hamdy RF, Kossoff EH. Infantile spasms treated with the ketogenic diet: Prospective single-center experience in 104 consecutive infants. Epilepsia 2010;51:1403–1407.

e5.Zafeiriou D, Kontopoulos E, Tsikoulas I. Adrenocorticotropic hormone and vigabatrin treatment of children with infantile spasms underlying cerebral palsy. Brain and Development 1996;18:450–452.

e6.Schlumberger E, Dulac O. A simple effective and well-tolerated treatment regime for West syndrome. Dev Med Child Neurol 1994;36:863–872.

e7.Debus OM, Kurlemann G, Study g. Sulthiame in the primary therapy of West syndrome: a randomized double-blind placebo-controlled add-on trial on baseline pyridoxine medication. Epilepsia 2004;45:103–108.

e8.Zou L-P, Wang X, Dong C-H, Chen C-H, Zhao W, Zhao R-Y. Three-week combination treatment with ACTH + magnesium sulfate versus ACTH monotherapy for infantile spasms: a 24-week, randomized, open-label, follow-up study in China. Clinical Therapeutics 2010;32:692–700.

e9.Siemes H, Brandl U, Spohr H-L. Long-term follow-up study of vigabatrin in pretreated children with West syndrome. Seizure 1998;7:293–297.

e10.Granstrom M-L, Gaily E, Liukkonen E. Treatment of infantile spasms: results of a population-based study with vigabatrin as the first drug for spasms. Epilepsia 1999;40:950–957.

e11.Glaze DG, Hrachovy RA, Frost JD, Jr., Kellaway P, Zion TE. Prospective study of outcome of infants with infantile spasms treated during controlled studies of ACTH and prednisone. J Pediatr 1988;112:389–396.

e12.Ohtsuka Y, Murashima I, Oka E, Ohtahara S. Treatment and prognosis of West syndrome. Journal of Epilepsy 1994;7:279–284.

e13.Holden KR, Clarke SL, Griesemer DA. Long-term outcomes of conventional therapy for infantile spasms. Seizure 1997;6:201–205.

e14.Darke K, Edwards SW, Hancock E, et al. Developmental and epilepsy outcomes at age 4 years in the UKISS trial comparing hormonal treatments to vigabatrin for infantile spasms: a multi-centre randomized trial. Arch Dis Child 2010;95:382–386.

e15.O'Callaghan FJK, Lux AL, Darke K, et al. The effect of lead time to treatment and of age of onset on developmental outcome at 4 years in infantile spasms: Evidence from the United Kingdom Infantile Spasms Study. Epilepsia 2011;52:1359–1364.

e16.Cohen-Sadan S, Kramer U, Ben-Zeev B, et al. Multicenter long-term follow-up of children with idiopathic West syndrome: ACTH versus vigabatrin. European Journal of Neurology 2009;16:482–487.

e17.Kivity S, Lerman P, Ariel R, Danziger Y, Mimouni M, Shinnar S. Long-term cognitive outcomes of a cohort of children with cryptogenic infantile spasms treated with high-dose adrenocorticotropic hormone. Epilepsia 2004;45:255–262.

e18.Lin H-C, Young C, Wang P-J, Lee W-T, Shen Y-Z. ACTH therapy for Taiwanese children with West syndrome -- efficacy and impact on long-term prognosis. Brain Dev 2006;28:196–201.

e19.Hardus P, Verduin WM, Engelsman M, et al. Visual field loss associated with vigabatrin: quantification and relation to dose. Epilepsia 2001;42:262–267.

e20.Vanhatalo S, Nousiainen I, Eriksson K, et al. Visual field constriction in 91 Finnish children treated with vigabatrin. Epilepsia 2002;43:748–756.

e21.Durbin S, Mirabella G, Buncic JR, Westall CA. Reduced grating acuity associated with retinal toxicity in children with infantile spasms on vigabatrin therapy. Investigative Ophthalmology and Visual Science 2009;50:4011–4016.

e22.Westall CA, Nobile R, Morong S, Buncic JR, Logan WJ, Panton CM. Changes in the electroretinogram resulting from discontinuation of vigabatrin in children. Doc Ophthalmol 2003;107:299–309.

e23.Mirabella G, Morong S, Buncic JR, et al. Contrast sensitivity is reduced in children with infantile spasms. Invest Ophthalmol Vis Sci 2007;48:3610–3615.

e24.McCoy B, Wright T, Weiss S, Go C, Westall CA. Electroretinogram changes in a pediatric population with epilepsy: Is vigabatrin acting alone? Journal of Child Neurology 2011;26:729–733.

e25.Wheless JW, Carmant L, Bebin M, et al. Magnetic resonance imaging abnormalities associated with vigabatrin in patients with epilepsy. Epilepsia 2009;50:195–205.

e26.Simao GN, Zarei Mahmoodabadi S, Snead OC, Go C, Widjaja E. Abnormal axial diffusivity in the deep gray nuclei and dorsal brain stem in infantile spasm treated with vigabatrin. AJNR Am J Neuroradiol 2011;32:199–203.

e27.Westall CA, Morong SE, Buncie JR, Logan W. Importance of baseline for electrophysiology assessment of drug induced changes in children with seizures. Journal of Vision 2002;2:92a.

e28. Kossoff EH, Hartman AL, Rubenstein JE, Vining EPG. High-dose oral prednisolone for infantile spasms: An effective and less expensive alternative to ACTH. Epilepsy and Behavior 2009;14:674‒676.

e29. Kondo Y, Okumura A, Watanabe K, et al. Comparison of two low dose ACTH therapies for West syndrome: their efficacy and side effect. Brain & Development 2005;27:326‒330.

e30. Oguni H, Yanagaki S, Hayashi K, et al. Extremely low-dose ACTH step-up protocol for West syndrome: maximum therapeutic effect with minimal side effects. Brain & Development 2006;28:8‒13.

e31. Glauser TA, Clark PO, McGee K. Long-term response to topiramate in patients with West syndrome. Epilepsia 2000;41:S91‒S94.

e32. Valencia I, Fons C, Kothare SV, et al. Efficacy and tolerability of topiramate in children younger than 2 years old. Journal of Child Neurology 2005;20:667‒669.

e33. Kwon Y-S, Jun Y-H, Hong Y-J, Son B-K. Topiramate monotherapy in infantile spasm. Yonsei Medical Journal 2006;47:498‒504.

e34. Hosain SA, Merchant S, Solomon GE, Chutorian A. Topiramate for the treatment of infantile spasms. Journal of Child Neurology 2006;21:17‒19.

e35. Zou L-P, Ding C-H, Fang F, Sin N-C, Mix E. Prospective study of first-choice topiramate therapy in newly diagnosed infantile spasms. Clinical Neuropharmacology 2006;29:343‒349.

e36. Peltzer B, Alonso WD, Porter BE. Topiramate and adrenocorticotropic hormone (ACTH) as initial treatment for infantile spasms. Journal of Child Neurology 2009;24:400‒405.

e37. Kossoff EH, Hedderick EF, Turner Z, Freeman JM. A case-control evaluation of the ketogenic diet versus ACTH for new-onset infantile spasms. Epilepsia 2008;49:1504‒1509.

e38. Hong AM, Turner Z, Hamdy RF, Kossoff EH. Infantile spasms treated with the ketogenic diet: Prospective single-center experience in 104 consecutive infants. Epilepsia 2010;51:1403‒1407.